Ibuprofen and diclofenac treatments reduce proliferation of pancreatic acinar cells upon inflammatory injury and mitogenic stimulation

British Journal of Pharmacology

Volumn 175, Issue 2, 2018, Pages 335-347

  Bombardo, Marta ^a   Malagola, Ermanno ^a   Chen, Rong ^a   Rudnicka, Alina ^a   Graf, Rolf ^a,b   Sonda, Sabrina ^a,b,c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY OF TASMANIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DICLOFENAC; IBUPROFEN; LIOTHYRONINE; CERULETIDE; MITOGENIC AGENT;

ACINAR CELL; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMICAL ANALYSIS; CELL ACTIVATION; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL DIVISION; CELL PROLIFERATION; CERULEIN-INDUCED PANCREATITIS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; HISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MALE; METAPLASIA; MITOGENESIS; MOUSE; NONHUMAN; POLARIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CYTOLOGY; INFLAMMATION; METABOLISM; NEUTROPHIL CHEMOTAXIS; PANCREAS; PANCREATITIS; PATHOLOGY;

ACINAR CELLS; ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; CERULETIDE; CYTOKINES; DICLOFENAC; IBUPROFEN; INFLAMMATION; MALE; MICE; MITOGENS; NEUTROPHIL INFILTRATION; PANCREAS; PANCREATITIS; TRIIODOTHYRONINE;

EID: 85020849767     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13867     Document Type: Article

References (63)

1. Alexander SPH, Davenport AP, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015a). The concise guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. Br J Pharmacol 172: 5744–5869.
2. Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015b). The concise guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol 172: 6024–6109.
3. Andrews J, Djakiew D, Krygier S, Andrews P (2002). Superior effectiveness of ibuprofen compared with other NSAIDs for reducing the survival of human prostate cancer cells. Cancer Chemother Pharmacol 50: 277–284.
4. Araki Y, Okamura S, Hussain SP, Nagashima M, He P, Shiseki M et al. (2003). Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Cancer Res 63: 728–734.
5. Bang UC, Semb S, Nojgaard C, Bendtsen F (2008). Pharmacological approach to acute pancreatitis. World J Gastroenterol 14: 2968–2976.
6. Banks PA, Conwell DL, Toskes PP (2010). The management of acute and chronic pancreatitis. Gastroenterol Hepatol (N Y) 6: 1–16.
7. Baron JA, Sandler RS (2000). Nonsteroidal anti-inflammatory drugs and cancer prevention. Annu Rev Med 51: 511–523.
8. Bonelli P, Tuccillo FM, Calemma R, Pezzetti F, Borrelli A, Martinelli R et al. (2011). Changes in the gene expression profile of gastric cancer cells in response to ibuprofen: a gene pathway analysis. Pharmacogenomics J 11: 412–428.
9. Bushra R, Aslam N (2010). An overview of clinical pharmacology of ibuprofen. Oman Med J 25: 155–1661.
10. Chai AC, Robinson AL, Chai KX, Chen LM (2015). Ibuprofen regulates the expression and function of membrane-associated serine proteases prostasin and matriptase. BMC Cancer 15: 1025.
11. Chavez ML, Dekorte CJ (2003). Valdecoxib: a review. Clin Ther 25: 817–851.
12. Connizzo BK, Yannascoli SM, Tucker JJ, Caro AC, Riggin CN, Mauck RL et al. (2014). The detrimental effects of systemic ibuprofen delivery on tendon healing are time-dependent. Clin Orthop Relat Res 472: 2433–2439.
13. Cory S, Huang DC, Adams JM (2003). The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 22: 8590–8607.
14. Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SP, Giembycz MA et al. (2015). Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J Pharmacol 172: 3461–3471.
15. Dannoura A, Giraldo A, Pereira I, Gibbins JM, Dash PR, Bicknell KA et al. (2014). Ibuprofen inhibits migration and proliferation of human coronary artery smooth muscle cells by inducing a differentiated phenotype: role of peroxisome proliferator-activated receptor gamma. J Pharm Pharmacol 66: 779–792.
16. Elsisi NS, Darling-Reed S, Lee EY, Oriaku ET, Soliman KF (2005). Ibuprofen and apigenin induce apoptosis and cell cycle arrest in activated microglia. Neurosci Lett 375: 91–96.
17. Endo H, Yano M, Okumura Y, Kido H (2014). Ibuprofen enhances the anticancer activity of cisplatin in lung cancer cells by inhibiting the heat shock protein 70. Cell Death Dis 5: e1027.
18. Fajardo AM, Piazza GA (2015). Chemoprevention in gastrointestinal physiology and disease. Anti-inflammatory approaches for colorectal cancer chemoprevention. Am J Physiol Gastrointest Liver Physiol 309: G59–G70.
19. Gomes RN, Colquhoun A (2012). E series prostaglandins alter the proliferative, apoptotic and migratory properties of T98G human glioma cells in vitro. Lipids Health Dis 11: 171.
20. Gourevitch D, Kossenkov AV, Zhang Y, Clark L, Chang C, Showe LC et al. (2014). Inflammation and its correlates in regenerative wound healing: an alternate perspective. Adv Wound Care (New Rochelle) 3: 592–603.
21. Graf R, Schiesser M, Lussi A, Went P, Scheele GA, Bimmler D (2002). Coordinate regulation of secretory stress proteins (PSP/reg, PAP I, PAP II, and PAP III) in the rat exocrine pancreas during experimental acute pancreatitis. J Surg Res 105: 136–144.
22. Greenspan EJ, Madigan JP, Boardman LA, Rosenberg DW (2011). Ibuprofen inhibits activation of nuclear β-catenin in human colon adenomas and induces the phosphorylation of GSK-3β. Cancer Prev Res (Phila) 4: 161–171.
23. Grosch S, Maier TJ, Schiffmann S, Geisslinger G (2006). Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 98: 736–747.
24. Gu P, Su Y, Guo S, Teng L, Xu Y, Qi J et al. (2008). Over-expression of COX-2 induces human ovarian cancer cells (CAOV-3) viability, migration and proliferation in association with PI3-k/Akt activation. Cancer Invest 26: 822–829.
25. Gurpinar E, Grizzle WE, Piazza GA (2014). NSAIDs inhibit tumorigenesis, but how? Clin Cancer Res 20: 1104–1113.
26. He C, Tsuchiyama SK, Nguyen QT, Plyusnina EN, Terrill SR, Sahibzada S et al. (2014). Enhanced longevity by ibuprofen, conserved in multiple species, occurs in yeast through inhibition of tryptophan import. PLoS Genet 10: e1004860.
27. Ikegaki N, Hicks SL, Regan PL, Jacobs J, Jumbo AS, Leonhardt P et al. (2014). S(+)-ibuprofen destabilizes MYC/MYCN and AKT, increases p53 expression, and induces unfolded protein response and favorable phenotype in neuroblastoma cell lines. Int J Oncol 44: 35–43.
28. Janssen GM, Venema JF (1985). Ibuprofen: plasma concentrations in man. J Int Med Res 13: 68–73.
29. Johnson CC, Hayes RB, Schoen RE, Gunter MJ, Huang WY, Team PT (2010). Non-steroidal anti-inflammatory drug use and colorectal polyps in the prostate, lung, colorectal, and ovarian cancer screening trial. Am J Gastroenterol 105: 2646–2655.
30. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577–1579.
31. Kowalik MA, Perra A, Pibiri M, Cocco MT, Samarut J, Plateroti M et al. (2010). TRbeta is the critical thyroid hormone receptor isoform in T3-induced proliferation of hepatocytes and pancreatic acinar cells. J Hepatol 53: 686–692.
32. Ledda-Columbano GM, Perra A, Pibiri M, Molotzu F, Columbano A (2005). Induction of pancreatic acinar cell proliferation by thyroid hormone. J Endocrinol 185: 393–399.
33. Leidgens V, Seliger C, Jachnik B, Welz T, Leukel P, Vollmann-Zwerenz A et al. (2015). Ibuprofen and diclofenac restrict migration and proliferation of human glioma cells by distinct molecular mechanisms. PLoS One 10: e0140613.
34. Liou GY, Doppler H, Necela B, Krishna M, Crawford HC, Raimondo M et al. (2013). Macrophage-secreted cytokines drive pancreatic acinar-to-ductal metaplasia through NF-kappaB and MMPs. J Cell Biol 202: 563–577.
35. Liou GY, Storz P (2015). Inflammatory macrophages in pancreatic acinar cell metaplasia and initiation of pancreatic cancer. Oncoscience 2: 247–251.
36. Matos P, Jordan P (2015). Beyond COX-inhibition: ‘side-effects’ of ibuprofen on neoplastic development and progression. Curr Pharm Des 21: 2978–2982.
37. McGrath JC, Lilley E (2015). Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP. Br J Pharmacol 172: 3189–3193.
38. McWhorter FY, Wang T, Nguyen P, Chung T, Liu WF (2013). Modulation of macrophage phenotype by cell shape. Proc Natl Acad Sci U S A 110: 17253–17258.
39. Menter DG, Dubois RN (2012). Prostaglandins in cancer cell adhesion, migration, and invasion. Int J Cell Biol 2012: 723419.
40. Minshall C, Arkins S, Straza J, Conners J, Dantzer R, Freund GG et al. (1997). IL-4 and insulin-like growth factor-I inhibit the decline in Bcl-2 and promote the survival of IL-3-deprived myeloid progenitors. J Immunol 159: 1225–1232.
41. Murray B, Carter R, Imrie C, Evans S, O'suilleabhain C (2003). Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. Gastroenterology 124: 1786–1791.
42. Paisley P, Kinsella J (2014). Pharmacological management of pain in chronic pancreatitis. Scott Med J 59: 71–79.
43. Pezzilli R, Morselli-Labate AM, Corinaldesi R (2010). NSAIDs and acute pancreatitis: a systematic review. Pharmaceuticals 3: 558–571.
44. Piazza GA, Keeton AB, Tinsley HN, Whitt JD, Gary BD, Mathew B et al. (2010). NSAIDs: old drugs reveal new anticancer targets. Pharmaceuticals (Basel) 3: 1652–1667.
45. Pugazhenthi S, Miller E, Sable C, Young P, Heidenreich KA, Boxer LM et al. (1999). Insulin-like growth factor-I induces bcl-2 promoter through the transcription factor cAMP-response element-binding protein. J Biol Chem 274: 27529–27535.
46. Reddy BS, Tokumo K, Kulkarni N, Aligia C, Kelloff G (1992). Inhibition of colon carcinogenesis by prostaglandin synthesis inhibitors and related compounds. Carcinogenesis 13: 1019–1023.
47. Rome LH, Lands WE (1975). Structural requirements for time-dependent inhibition of prostaglandin biosynthesis by anti-inflammatory drugs. Proc Natl Acad Sci U S A 72: 4863–4865.
48. Salama RA, El Gayar NH, Georgy SS, Hamza M (2016). Equivalent intraperitoneal doses of ibuprofen supplemented in drinking water or in diet: a behavioral and biochemical assay using antinociceptive and thromboxane inhibitory dose-response curves in mice. PeerJ 4: e2239.
49. Saluja A, Dudeja V (2008). Heat shock proteins in pancreatic diseases. J Gastroenterol Hepatol 23 (Suppl 1): S42–S45.
50. Sheng H, Shao J, Washington MK, Dubois RN (2001). Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 276: 18075–18081.
51. Shrivastava P, Bhatia M (2010). Essential role of monocytes and macrophages in the progression of acute pancreatitis. World J Gastroenterol 16: 3995–4002.
52. Silva A, Weber A, Bain M, Reding T, Heikenwalder M, Sonda S et al. (2011). COX-2 is not required for the development of murine chronic pancreatitis. Am J Physiol Gastrointest Liver Physiol 300: G968–G975.
53. Simmons DL, Botting RM, Hla T (2004). Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 56: 387–437.
54. Simon AM, O'connor JP (2007). Dose and time-dependent effects of cyclooxygenase-2 inhibition on fracture-healing. J Bone Joint Surg Am 89: 500–511.
55. Sotoudehmanesh R, Khatibian M, Kolahdoozan S, Ainechi S, Malboosbaf R, Nouraie M (2007). Indomethacin may reduce the incidence and severity of acute pancreatitis after ERCP. Am J Gastroenterol 102: 978–983.
56. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SP et al. (2016). The IUPHAR/BPS guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucleic Acids Res 44: D1054–D1068.
57. Taketo MM (1998). Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst 90: 1529–1536.
58. Tegeder I, Pfeilschifter J, Geisslinger G (2001). Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 15: 2057–2072.
59. Ulrich CM, Bigler J, Potter JD (2006). Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 6: 130–140.
60. Vainio H (2001). Is COX-2 inhibition a panacea for cancer prevention? Int J Cancer 94: 613–614.
61. Wang D, Dubois RN (2010). Eicosanoids and cancer. Nat Rev Cancer 10: 181–193.
62. Wiktorowska-Owczarek A, Namiecinska M, Owczarek J (2015). The effect of ibuprofen on bFGF, VEGF secretion and cell proliferation in the presence of LPS in HMEC-1 cells. Acta Pol Pharm 72: 889–894.
63. Zhang X, Morham SG, Langenbach R, Young DA (1999). Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J Exp Med 190: 451–459.